Gilead Sciences (GILD) Short term Debt (2009 - 2026)
Gilead Sciences' (GILD) quarterly Short term Debt came in at $1.3 billion in Q1 2026, down 53.21% YoY from $2.8 billion in Q1 2025, and down 53.22% on a QoQ basis from $2.8 billion in Q4 2025.
Gilead Sciences (GILD) Short term Debt (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Short term Debt data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Short term Debt fell 53.21% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 53.21% YoY) and the FY2025 annual result came in at $2.8 billion, up 54.66% from the prior year.
- Short term Debt slipped to $1.3 billion in Q1 2026, from $2.8 billion in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $4.0 billion in Q2 2023 to a low of $1.0 billion in Q2 2022.
- A 5-year average of $2.2 billion and a median of $2.3 billion in 2022 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2023 — Short term Debt surged 295.4% — and 2024, when it slumped 55.16%.
- Tracing GILD's Short term Debt over 5 years: stood at $2.3 billion in 2022, then retreated by 20.9% to $1.8 billion in 2023, then gained by 0.95% to $1.8 billion in 2024, then jumped by 54.66% to $2.8 billion in 2025, then sank by 53.22% to $1.3 billion in 2026.
- The last three Short term Debt figures came in at $1.3 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.81 Bn | 633.06 Bn | 17.26 Bn |
| 2 | AbbVie | 469.85 Bn | 463.28 Bn | 12.70 Bn |
| 3 | Merck | 375.13 Bn | 367.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.67 Bn | 294.98 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn |
| 6 | Amgen | 237.08 Bn | 223.09 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.35 Bn | 180.18 Bn | 6.22 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.41 Bn |
| Mar 31, 2026 | 1.31 Bn |
| Dec 31, 2025 | 2.81 Bn |
| Sep 30, 2025 | 2.81 Bn |
| Jun 30, 2025 | 2.81 Bn |
| Mar 31, 2025 | 2.81 Bn |
| Dec 31, 2024 | 1.82 Bn |
| Sep 30, 2024 | 1.81 Bn |
| Jun 30, 2024 | 1.81 Bn |
| Mar 31, 2024 | 3.67 Bn |
| Dec 31, 2023 | 1.80 Bn |
| Sep 30, 2023 | 1.79 Bn |
| Jun 30, 2023 | 4.04 Bn |
| Mar 31, 2023 | 2.28 Bn |
| Dec 31, 2022 | 2.27 Bn |
| Sep 30, 2022 | 2.27 Bn |
| Jun 30, 2022 | 1.02 Bn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 1.52 Bn |
| Sep 30, 2021 | 2.51 Bn |